A vice president at Memorial Sloan Kettering received a stake of nearly $1.4 million in a biotech company for representing the hospital on its board. He will give back his stake as the cancer center grapples with questions about conflicts of interest.
A ProPublica analysis found that black people and Native Americans are under-represented in clinical trials of new drugs, even when the treatment is aimed at a type of cancer that disproportionately affects them.
Dr. José Baselga, the hospital's chief medical officer, stepped down days after a report by ProPublica and the New York Times that he failed to disclose millions of dollars in payments from the health care and drug industry in research articles.
The CMS inspector’s notes suggest a tense and dysfunctional transition more than two years ago as the heart transplant program, long known as one of the best in the nation, made staffing changes aimed at improving care.
Memorial Sloan Kettering Cancer Center CMO José Baselga has received millions of dollars in payments from companies that are involved in medical research. His omissions expose how weakly conflict-of-interest rules are enforced by journals.
Carolyn Dineen King, a senior U.S. Circuit Court judge, resigned from the St. Luke's board on May 30, two weeks after ProPublica and the Houston Chronicle detailed deaths and complications in the famed heart program.